PPROM Erythromycin Versus Azithromycin (PEACE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01431248|
Recruitment Status : Completed
First Posted : September 9, 2011
Last Update Posted : January 16, 2013
|Condition or disease|
|Preterm Premature Rupture of Membranes|
|Study Type :||Observational|
|Actual Enrollment :||7 participants|
|Official Title:||Preterm Premature Rupture of Membranes: Erythromycin Versus Azithromycin. A Randomized Trial Comparing Their Efficacy to Prolong Latency|
|Study Start Date :||September 2011|
|Actual Primary Completion Date :||January 2013|
|Actual Study Completion Date :||January 2013|
Azithromycin 1gm PO once
Erythromycin 250mg IV Q 6hrs x 48 hours followed by 500 mg PO Q 8 hours x 5 days.
- Time to delivery [ Time Frame: 2 years ]To compare the mean time to delivery, using azithromycin versus erythromycin to prolong latency in PPROM patients. The working hypothesis for this aim is that there is no difference in the clinical effectiveness between antibiotic regimens containing the macrolides azithromycin and erythromycin for prolonging latency in PPROM.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01431248
|Principal Investigator:||Eric Knudtson, MD||University of Oklahoma|